Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 6;22(1):123.
doi: 10.1186/s12957-024-03393-7.

Adjuvant chemotherapy omission after pancreatic cancer resection: a French nationwide study

Charles Poiraud  1   2 , Xavier Lenne  3   2 , Amélie Bruandet  3   2 , Didier Theis  3   2 , Nicolas Bertrand  4   2 , Anthony Turpin  4   2 , Stephanie Truant  1   2 , Mehdi El Amrani  5   6   7
Affiliations

Adjuvant chemotherapy omission after pancreatic cancer resection: a French nationwide study

Charles Poiraud et al. World J Surg Oncol. .

Abstract

Background: Adjuvant chemotherapy (AC) improves the prognosis after pancreatic ductal adenocarcinoma (PDAC) resection. However, previous studies have shown that a large proportion of patients do not receive or complete AC. This national study examined the risk factors for the omission or interruption of AC.

Methods: Data of all patients who underwent pancreatic surgery for PDAC in France between January 2012 and December 2017 were extracted from the French National Administrative Database. We considered "omission of adjuvant chemotherapy" (OAC) all patients who failed to receive any course of gemcitabine within 12 postoperative weeks and "interruption of AC" (IAC) was defined as less than 18 courses of AC.

Results: A total of 11 599 patients were included in this study. Pancreaticoduodenectomy was the most common procedure (76.3%), and 31% of the patients experienced major postoperative complications. OACs and IACs affected 42% and 68% of the patients, respectively. Ultimately, only 18.6% of the cohort completed AC. Patients who underwent surgery in a high-volume centers were less affected by postoperative complications, with no impact on the likelihood of receiving AC. Multivariate analysis showed that age ≥ 80 years, Charlson comorbidity index (CCI) ≥ 4, and major complications were associated with OAC (OR = 2.19; CI95%[1.79-2.68]; OR = 1.75; CI95%[1.41-2.18] and OR = 2.37; CI95%[2.15-2.62] respectively). Moreover, age ≥ 80 years and CCI 2-3 or ≥ 4 were also independent risk factors for IAC (OR = 1.54, CI95%[1.1-2.15]; OR = 1.43, CI95%[1.21-1.68]; OR = 1.47, CI95%[1.02-2.12], respectively).

Conclusion: Sequence surgery followed by chemotherapy is associated with a high dropout rate, especially in octogenarian and comorbid patients.

Keywords: Adjuvant chemotherapy; Hospital volume; Pancreatic adenocarcinoma; Pancreatic cancer surgery.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

References

    1. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–21. doi: 10.1158/0008-5472.CAN-14-0155. - DOI - PubMed
    1. Conroy T, Ducreux M. Adjuvant treatment of pancreatic cancer. Curr Opin Oncol. 2019;31(4):346–53. doi: 10.1097/CCO.0000000000000546. - DOI - PubMed
    1. Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul J-L, et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med. 2018;379(25):2395–406. doi: 10.1056/NEJMoa1809775. - DOI - PubMed
    1. Bertens KA, Massman JD, Helton S, Garbus S, Mandelson MM, Lin B, et al. Initiation of adjuvant therapy following surgical resection of pancreatic ductal adenocarcinoma (PDAC): are patients from rural, remote areas disadvantaged? J Surg Oncol. 2018;117(8):1655–1563. doi: 10.1002/jso.25060. - DOI - PubMed
    1. Valle JW, Palmer D, Jackson R, Cox T, Neoptolemos JP, Ghaneh P, et al. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol off J Am Soc Clin Oncol. 2014;32(6):504–12. doi: 10.1200/JCO.2013.50.7657. - DOI - PubMed

MeSH terms